A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults

Official title

A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE DOSE-ESCALATION AND MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-07985631 IN HEALTHY ADULT PARTICIPANTS

Overview

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07985631) for the possible treatment of a kidney disease called IgA nephropathy. This study is seeking participants who * are male or female between 18 and 45 years of age (55 for Japanese/Chinese/multiple dose participants) * are deemed to be healthy Participants in this study will receive PF-07985631 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07985631 or placebo will be given as a small needle injection (in the abdomen, thigh or back of the arm) or as an IV infusion in the arm (given directly into a vein) at the study clinic. Most participants will receive PF-07985631 or placebo one time. Some participants may receive PF-07985631 or placebo once a month for 3 months. The study will compare the experiences of people receiving PF-07985631 to those of the people who do not. This will help decide if PF-07985631 is safe and effective. Participants who take PF-07985631 or placebo only 1 time will take part in this study for about 4 months. During this time, they will stay at the study clinic for 11 to 14 days and will have 8 more study visits at the study clinic. Participants who take PF-07985631 or placebo more than once will take part in this study for about 6 months. During this time, they will stay at the study clinic for about 4 days a month 3 times and will have 10 more study visits at the study clinic. During study clinic stays and study visits, blood samples will be done and safety reviews completed.

Interventions

• Drug PF-07985631
  Experimental Pfizer compound which will be SC or IV
• Drug Placebo
  Placebo which will be SC or IV

Primary outcome measures

• Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) [Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)]
• Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria [Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)]
• Number of Participants With Notable Electrocardiogram (ECG) Values [Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)]
• Number of Participants With Clinically Significant Abnormal Laboratory Parameters [Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)]

Secondary outcome measures (6)

• Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau): MD cohorts only [Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)]
• Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): SAD cohorts only [Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)]
• Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): SAD cohorts only [Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)]
• Maximum Observed Plasma Concentration (Cmax) [Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)]
• Time to Reach Maximum Observed Plasma Concentration (Tmax) [Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)]
• Plasma Decay Half-Life (t1/2): SAD cohorts only [Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)]

Eligibility criteria

Inclusion:

• Between 18 and 45 years of age who are overtly healthy.
• Japanese/Chinese and multiple dose cohorts only: Adult participants 18 to 55 years of age who are overtly healthy may be eligible at the discretion of PI.
• Japanese/Chinese cohorts only: Participants must have 4 biological Japanese/Chinese grandparents who were born in Japan/China.

Exclusion:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Participants with a history of allergic or anaphylactic reaction with any investigative biologic agents.
• History of infections requiring treatment within 28 days prior to Day 1 or any active infection at Day 1.
• Active or latent infection with tuberculosis.
• History of recurrent urinary tract infections AND/OR sinopulmonary infections AND/OR gastrointestinal infections requiring antibiotic treatment.
• Known fever within the 7 days prior to dosing.
• Active gastrointestinal (GI) tract ulcerations or GI bleeding.
• Vaccination within 6 weeks prior to Day 1 dosing or planned vaccination during the study.
• Positive urine drug test.
• Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic).
• Estimated glomerular filtration rate (eGFR) <75 mL/min/1.73 m².
• Chest X-ray showing any active disease in the chest, or pulmonary nodules >0.5 cm in diameter that have not been previously evaluated, cavitary lesions or evidence of bronchiectasis.
• Standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
• Positive stool hematest at screening or admission.
• Participants with ANY of the following abnormalities in clinical laboratory tests at screening:

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (direct and total) ≥1.05 × upper limit of normal
• Immunoglobulin G, Immunoglobulin M, Immunoglobulin A below the lower limit of normal (LLN)
• Total white blood cell (WBC) below the LLN
• Lymphocyte count below the LLN
• Platelet count below the LLN
• Hemoglobin below the LLN

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Sequential

Masking

Double blind

Primary purpose

Basic science

Study locations

Belgium · 1 center

• Pfizer Clinical Research Unit - Brussels — Brussels

Identifiers

NCT: NCT06994897 · C5661001 · 2024-519215-33-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗